
|Articles|July 8, 2014
- Hematologic Malignancies
- Volume 1
- Issue 1
Resistance to Ibrutinib
Author(s)John C. Byrd, MD
John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses resistance to ibrutinib.
Advertisement
John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses resistance to ibrutinib.
View more about the treatment of chronic lymphocytic leukemia > >
Articles in this issue
almost 12 years ago
Comorbidities, Age, and Outcomes Among Intensively Treated Patients With AMLalmost 12 years ago
In the Pipeline: Potential New Treatments for AMLalmost 12 years ago
Epidemiology in B-Cell Malignanciesalmost 12 years ago
Pathogenesis of Follicular Lymphomaalmost 12 years ago
IPI-145 and ABT-199 for Lymphoid Malignanciesalmost 12 years ago
BCL-2 Inhibitor Combo May Offer Remissions in CLLalmost 12 years ago
In Practice: Challenges in Treating Patients With Relapsed or Refractory CLLAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5

































